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Aim: The aim of this clinical audit was to assess patient-reported outcomes on the effect of dietary intervention, to enhance our 
understanding of possible treatment options in irritable bowel syndrome (IBS). 
Background: A large number of food-related gastro-intestinal disorders have been attributed to IBS for decades.  
Methods: Patient-reported outcomes from the records of 149 IBS patients treated at secondary and tertiary Gastroenterology outpatients 
in two UK hospitals between January 2014 and July 2016 were audited. Patients all presented with symptoms fulfilling Rome III-IV 
criteria for IBS had negative coeliac serology and did not have other gastrointestinal (GI) conditions. A modified version of a low 
FODMAP diet had been recommended (gluten and lactose free diet (G/LFD)) and was implemented for 6 weeks. Outcomes and dietary 
adherence were recorded during outpatient’s consultations.   
Results: A total of 134 patients complied with the diet optimally. The majority had an improvement rate >70% and continued with 
the diet. Fifty-three percent became completely or almost asymptomatic, while 27.6% had a poor response to the diet (scoring < 30%) 
to G/LFD. The improvement was excellent in patients with normal BMI and good in overweight and obese and where BMI <18. Over 
50% did not require any follow-up within 12 months.  
Conclusion: Although it is unclear whether symptoms are triggered by gluten, fructans or lactose, elimination of gluten and lactose 
proved to be an effective treatment in patients with IBS. Multidisciplinary team management and implementation of detailed nutrition 
therapy using the audit algorithm might prove to be both cost effective and efficacious a treatment option in IBS.  
Keywords: NCGS, Gluten, Fructans, Amylase trypsin inhibitors, FODMAP, Lactose intolerance, Irritable bowel syndrome. 
(Please cite as: Rostami K, Bold J, Ali JE, Parr A, Dieterich W, Zopf Y, et al. An algorithm for differentiating food 
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Introduction  
  1 Irritable bowel syndrome (IBS) is a collection of 
gastrointestinal symptoms that was defined 4 decades 
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ago when no organic causes were identified for the 
symptoms. Due to multiple etiologies, the pathogenesis 
of IBS is poorly understood.  
The Manning criteria were originally developed in 
1978 (1), followed by the Rome criteria in 1992. The 
Rome Criteria have been periodically revised (Rome IV 
criteria) to enable the health professional to filter the 
functional from organic disorders (2). Both Manning 
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and Rome criteria have been criticized for their low 
specificity. In recently published Rome IV criteria, 
some of previously considered functional conditions 
have been removed from the IBS box (3) as a clear 
pathophysiology, and a distinct immunopathology were 
identified for these conditions. This has most likely 
contributed to a recently reported reduced incidence of 
IBS (4). 
Discovery of foods high in FODMAP (including wheat 
and milk products) as a triggering factor for some IBS 
patients has revolutionized our understanding on 
etiopathogenesis of IBS. It has explained that food 
sensitivity triggers symptoms in a substantial number of 
patients under IBS umbrella (5). Studies demonstrate 
that many patients with IBS benefit from a low 
FODMAP diet (6). However, the long-term 
implications of following a low-FODMAP diet are 
poorly understood and there is a risk of both poor diet 
quality (7) and microbiome harm (8).  Wheat is high in 
fructans and is a staple food in many cultures; thus, 
exclusion of wheat and gluten-containing foods can be 
a simpler way of reducing FODMAPs without wider 
dietary restriction of all FODMAP-rich foods, many of 
which are fruits and vegetables. Prior to the discovery 
of food implications in IBS, patients presenting with 
gastrointestinal symptoms who were compatible with 
Rome I-IV criteria were treated only symptomatically 
with medications without exploration of the underlying 
cause of symptoms. The symptom-control approach has 
been associated with patients’ dissatisfaction, 
additional anxiety and psychological consequences 
resulting from experiencing unresolved and persistent 
symptoms without a clear medical explanation. The 
downside of symptomatic treatment is not limited to 
patients’ dissatisfaction, rather it lacks long-term 
efficacy (9).  Moreover, the side effects of medications, 
the ongoing investigations and outpatient visits exhaust 
health-organization resources (10) and impair the 
quality of life of patients.  
There are several randomized controlled trials (11-14) 
suggesting that a large proportion of patients presenting 
with IBS symptoms would respond to dietary 
intervention, gluten-free diet (GFD) in particular. In 
these studies, quantities of gluten were used for 
challenge purposes (between 3-52g/day).  
Therefore, current evidence demonstrates that a large 
proportion of these patients can be treated effectively 
with a simpler version of low FODMAP comprising 
principally of a GFD. In addition, lactose intolerance is 
often a missed diagnosis (especially prevalent in multi-
cultural communities) and some patients with this 
condition eventually receive  medication instead of 
having lactose eliminated (15).  
The aim of this audit was to assess the outcomes 
achieved using a lactose and GFD clinical intervention 
in patients traditionally diagnosed with IBS.   
 
Methods 
This project was registered and approved by research 
development & audit department of both Worcester 
Acute and Milton Keynes University Hospitals (with 
registration number 993). This was an audit of 
outcomes from the records of 149 patients presenting 
with IBS symptoms at secondary and tertiary 
Gastroenterology outpatients in two UK hospitals 
between January 2014 and July 2016. All patients were 
presenting with symptoms consistent with Rome III-IV 
criteria. Organic disorders were excluded in patients 
with red flag signs like anaemia and weight loss via 
screening for coeliac disease or other gastrointestinal 
conditions. Lifestyle advice was given to overweight 
and obese patients to avoid hyperphagia by eating 
moderate portion sizes and ensuring adequate 
mastication. Patients were then offered a dietary 
intervention consisting of a gluten and lactose free diet 
(GF/LFD) for six weeks. Demographics, presenting 
symptoms, and serologic and histologic data were 
recorded. Clinical evaluation was performed using a 
self-administered instrument based on patient 
declaration during their outpatient’s consultations. 
Extra-intestinal Non Coeliac Gluten Sensitivity 
(NCGS) manifestations were recorded. The patients 
identified one to three main symptoms that were 
quantitatively assessed using a Numerical Rating Scale 
(NRS) with a score ranging from 1 (mild) to 10 
(severe) (16). The response was assessed for each 
parameter separately. A symptomatic response was a 
decrease of at least 30% of the baseline score. 
Responders were defined as patients who fulfilled the 
response criteria (> 30% reduction of one to three main 
symptoms or at least 1 symptom with no worsening of 
others). 
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Dietary adherence was evaluated during their follow-
ups. Patients were instructed and monitored by 
dietitians and gastroenterologists. Following dietary 
exclusion, a diagnosis of NCGS was made in some 
cases based on Salerno expert criteria (16) (however, as 
this was in a hospital outpatient clinical environment, 
an open gluten challenge was used instead of 
randomised double-blind placebo-controlled gluten 
challenge).  
Statistical analysis 
Data were expressed as mean ± standard deviation for 
numeric data and frequency (percent) for categorical 
data. Data were compared regarding different body 
mass indexes (BMI). Chi- square test, or alternatively 
Fisher test, was used for categorical data. P-value of 
less than 0.05 was considered as significant. 
 
Results 
A total of 134 out of 149 patients followed a 
Gluten- and lactose-free diet (G/LFD) and complied 
with the diet optimally. Fifty-six patients (41.8%) were 
from Milton Keynes University Hospital and 78 
(58.2%) from Worcester Acute Hospitals. A number of 
patients were tertiary referrals included in both centres. 
The ages of patients ranged from 8 to 85 years, with a 
mean age of 46.41 + 17.388 years. The majority (109) 
were females (81.3%), while the number of male 
patients was 25 (18.7%). 
As much as 72.4% (97/134 cases) showed 
significant improvement with a score in the range of 
40-100% (P=0.001), while 27.6% had a poor response 
with a score < 30%. From the group of responders, 
30/97 (32%) became completely asymptomatic. The 
improvement reported in the rest of responders (67/97) 
scored between 40-95%. Over 50% of the patients did 
not require a further follow-up within next 12 months 
owing to improvements in symptoms.  
In 110 patients, body mass index (BMI) was 
measured and from this group 10 (9 %) patients had 
low BMI, 34 (31%) normal BMI, 39 (35.5%) were 
overweight and 27 (24.5%) were obese. The best 
response to elimination diet was achieved in 27 cases 
with normal BMI followed by 28/39 in overweight 
range. There were no significant differences between 
response to elimination diet in patients with lower BMI 
<18 or obese (figure 1). The frequency of symptoms 
and response to GFD is summarized in Figure 2. 
 
 




Figure 2. Symptoms and response to GF/LFD 
 
 
Figure 3. Reported precipitating factors in the study 
population (%) 
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Table 1. The frequency of symptoms and response to the 
GF/LFD 
Symptoms Frequency (%) Response to GFD (%) 
Abdominal pain 109 (81.3) 80/109 (73.3) 
Diarrhoea 88(66) 66/88 (75) 
Constipation 46 (34) 29/46 (63) 
Bloating 73 (55) 51/73 (70) 
Reflux/Dyspepsia 54 (40) 39/54 (72.2) 
Weight loss 31 (23) 21/31 (91.3) 
Nausea/vomiting 15 (11) 10/15 (66.6) 
Anaemia 4 (3) 3/4 (75) 
Headache  19 (14) 17/19 (90) 
Skin change 6 (4) 6/6 (100) 
 
The most prevalent GI symptoms were abdominal 
pain at 109/134 (81.3%) followed by diarrhoea 88/134 
(66%), bloating 73/134 (55%), and heartburn 54/134 
(40%). The rate of improvement for abdominal pain 
scored as high as in 80/109 similar to diarrhoea in 
66/88 and bloating in 51/73. (Table 1) Surprisingly 
dyspeptic symptoms also improved in 39/54 (72.2%) in 
a similar range like diarrhoea and abdominal pain. 
(Table 1) A number of patients were able to stop or 
reduce taking their proton pump inhibitor (PPI) 
medication. Despite the restrictive nature of diet, 21/31 
with weight loss gained or maintained their weight. It 
should therefore be acknowledged that nutritional 
deficiency is common in patients with non-coeliac 
gluten-related disorders (17). Significant improvement 
was also reported in 10/15 patients with nausea and 
vomiting, 17/19 with headache, and 6/6 with skin 
changes (See Figure 2).  The triggering factors were 
assessed in 110/134 patients. In 62.3% of this group, 
we found a range of precipitating factors that included 
post gastroenteritis in 21/110 (19%), post 
cholecystectomy in 12/110 (11%), post pancreatitis in 
8/110 (7%), postpartum in 4/110 (3.6%), and anxiety 
and/or depression 24/110 (22%). Nevertheless, for 
41/110 (37%) there were no identifiable triggering 
factors identified (See Figure 3). 
 
Discussion 
IBS-like symptoms account for 40–60% of referrals 
to gastroenterology outpatient clinics (18). Prescribing 
analysis and cost tabulation (PACT) in the UK 
indicated that more than £70,000,000 has been spent on 
selected new laxatives and antispasmodics commonly 
used to treat IBS in primary care during 2012-2013 
(10). When patients are diagnosed and treated in 
secondary care, the total healthcare costs per patient 
substantially increases from 486 Euro (±3192) to 2328 
Euro (±5888) according to a Dutch study (19). 
Similarly, the average total direct medical 
cost/patient/year is estimated at USD 1.35 billion in the 
USA and 756.14±1592 euros per patient in France (20). 
The results of this clinical audit suggest that many 
patients of this group could potentially be managed 
more cost-effectively with dietary therapy. 
This audit has demonstrated that more than 70% of 
patients presenting with IBS symptoms improved by 
following a diet eliminating lactose and gluten 
containing grains (improvement for >30% in their 
symptoms). The variable response to dietary 
intervention suggests a multifactorial etiology to food 
sensitivity. The spectrum of variable responses to the 
gluten containing grain exclusion would suggest the 
possible overlapping (21) of other food antigens as 
outlined in figures 4 and 5. There was 40-95 % 
improvement in symptoms following elimination diet 
in 53% of our patients, which suggests sensitivity to 
gluten or other component confined to gluten 
containing grains or lactose. The lesser improvement 
rate might be associated with other factors like 
inadequate compliance with exclusion diet, possible 
implication of fructans (22) or anti-trypsin inhibitor 
(ATI) sensitivity.  
A diagnosis of IBS was applicable to 18% of 
patients included in this audit who had 0% response to 
elimination of gluten and lactose. Nevertheless, a 
comprehensive additional full FODMAP and ATI 
exclusion would be practically needed to be undertaken 
before a definite diagnosis of IBS is made in non-
responsive patients to gluten and lactose exclusion.  
The success of the elimination diet did not seem to 
be correlated with the body mass index (BMI). The best 
outcome was recorded in patients with normal BMI and 
also in the overweight group. Patients with higher BMI 
>30 or low below 18 also responded well to nutrition 
therapy. 
Based on this finding and spectrum of 
improvement, we proposed an algorithm in which food 
sensitivity could be differentiated from IBS. In this 
algorithm, gluten- and lactose-free diet stand as the first 
line of elimination intervention for patients presenting 
with IBS symptoms. This strategy is much less 
restricted compared to low FODMAP pathway with a 
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success rate in this audit of 72%. For those with lower 
improvement score, a full low FODMAP / ATI should 
be considered as the second line. Symptomatic 
treatment with medicines might be best considered in 
those who do not wish to undergo or respond to the 
elimination diet (See Figure 5 Algorithm). 
From a patient’s perspective, lack of a good 
explanation for symptoms may cause additional anxiety 
and depression (23, 24) so having an understanding of 
the cause of symptoms can also be beneficial.   
The symptoms related to non-coeliac gluten or 
fructans sensitivity are nearly identical to those of 
lactose intolerance or ATI related. Lactose intolerance 
(LI) in particular and secondary LI are common and 
underestimated. Despite the strong evidence suggesting 
high prevalence of this condition , a large proportion of 
 







ATI, FODMAP, Sulphate, 
Salicylates sensitivities? 
Anxiety and depression?
Improvement by treating any of 
above?









Symptoms not returned 
by gluten challenge  
NCGS or LI 
excluded
Symptoms return
Lifestyle; avoiding hyperphagia, reducing portion size, 





Figure 5. Algorithm to differentiate Gluten/Lactose//Fructans/ATIs sensitivity from IBS. LI=lactose intolerance. Six-week 
gluten- and lactose-free diet followed by one-week gluten challenge. When NCGS has been diagnosed or excluded, a 7-day 
Lactose challenge will follow to exclude or ascertain lactose intolerance. 
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both primary and secondary lactose intolerance are 
underestimated, labelled and treated like IBS with 
medications. Dietary advice is rarely provided by 
Gastroenterologists even though the impact of food-
related disorders compromise such high proportion of 
Gastroenterology outpatients. Astonishing 79% of 
Native Americans, 75% of African Americans, 51% of 
Hispanics, and 21% of Caucasians are reported to 
suffer from lactose maldigestion (25). In Africa, Asia, 
and Latin America, prevalence rates vary in the range 
15-100% depending on the population studied (25).  
Lactose, fructans and galacto oligosaccharides have 
strong biologic plausibility for symptom generation due 
to lack of hydrolases resulting in distention from 
osmosis and rapid fermentation (26). Lactose, gluten 
and other components of grains like ATIs are another 
major culprit for symptoms in a large proportion of 
patients fulfilling diagnostic criteria of IBS.  Wheat 
proteins have been reported to dysregulate the gut 
function (27) as antigenic wheat proteins activate innate 
lymphoid cell population (28) resulting in epithelial 
cells damage (29). They also lead to state of sensitivity 
with coeliac-like intestinal and extra-intestinal 
symptoms (30) that may present with mild or often 
invisible enteropathy in susceptible individuals (31). 
It is, however, unclear which component of grains 
are principal causes for these symptoms. Gluten (32), 
fructans (33) and ATIs (34) have been reported as 
major antigens in this equation. As far as we know, 
there is no published study that reliably demonstrates 
an exclusive antigenic property of any of these 3 
grains’ components (35). They may not be mutually 
exclusive either, as some individuals could potentially 
have sensitivity to both gluten and FODMAP.  
In accordance to some studies, excess fructose and 
polyols may only cause symptoms in specific 
individuals when consumed in high doses (26).  
The results of this audit are similar to a number of 
previous RCTs; most of the patients’ symptoms 
improved by avoiding gluten containing grains and 
lactose. The identification of the underlying cause for 
IBS symptoms was out of the scope of this audit, 
however.  
The clinical team reported that gluten-containing 
grains proved to be the main factor behind the 
symptoms of the majority of this group of patients. 
Nevertheless, evidence to prove this is not available 
from the audit as the clinical intervention included the 
exclusion of both lactose and gluten. In addition, it is 
impossible to identify from the records if it was the 
exclusion of lactose, gluten or indeed the other 
 
Figure 6. Spectrum of improvement and correlation with possible culprit 
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components of grains or perhaps a combination of these 
factors that provided the main benefit.   
Triggering factors 
The reason why the food sensitivity occurs at 
different stages of people’s lives has been a matter of 
debate.  
Environmental factors including an alteration of the 
gut microbiota (35) may be associated with NCGS and 
secondary lactose intolerance, but it is unclear whether 
dysbiosis is a primary or secondary event in the genesis 
of NCGS. The gut microbiota may change in patients 
following the events such as birth, infections, 
pancreatitis and surgeries (36, 37). These were found to 
be potential precipitating factors for developing NCGS 
in these individuals.  The origin of antigens cannot be 
inferred from this audit, but one can speculate antigens 
to have most likely originated from grain peptides. The 
FODMAP elements could possibly enhance the 
irritability component especially in patients with lower 
rate of improvement to gluten exclusion. The 
extraintestinal presentation can only be explained or 
induced by systemic inflammation (27, 31), which 
would support the potential grain antigenicity. The 
above complex pathophysiology would translate the 
environmental factors like gluten/ATI and FODMAP 
into an illustration (Figure 4, 5 and 6). 
Why should medication and symptomatic treatment 
be prescribed when elimination of triggers may prove 
beneficial?  Current guidelines such as the NICE 
guidelines in the UK for IBS recommend the use of 
medications (39), and less emphasis is currently put on 
the identification and elimination of triggers that may 
be present in the diet. In this audit, findings were 
similar to several RCT in that the majority of this group 
had an improvement rate over 70% following 
implementing a gluten and lactose elimination diet.  
This number and proportion of improvement is 
incomparable with any medications listed in NICE 
guideline for IBS (which provide symptomatic relief to 
around 50% of patients). Around 53% of the patients in 
this audit became completely or significantly 
asymptomatic. This indicates that the elimination of 
grains-containing gluten is an effective therapeutic 
intervention (9) in improving the symptoms. In this 
audit, improvement was not only recorded in patients 
with abdominal pain, diarrhoea and reflux disease, but 
also documented across a range of additional 
extraintestinal symptoms including joint pain, skin 
abnormalities, milder neuropathy, headache, fatigue 
and general well-being. 
This project was an audit and was not a randomised 
controlled trial, hence findings need to be considered in 
context of this limitation. However, findings are similar 
to a previous randomised double-blind placebo-
controlled study (13). Another limitation is that there 
was no differentiation between the lactose and gluten 
exclusion, which was not randomised, hence it is 
recommended that future research focus on 
investigating these areas.  
For all the outlined rationalization above, we would 
encourage healthcare and medical practice to consider 
differentiating food sensitivity from IBS as the 
treatment of these conditions are different (39). 
Identifying the group of patients with food sensitivity 
would open a prospect toward more targeted treatment 
that is more cost effective, with fewer side effects that 
could also potentially improve quality of life and 
patient satisfaction. New guidelines could support 
multidisciplinary team working, with joint dietitian and 
gastroenterologist clinics, for example. 
Findings from this clinical audit suggest that food 
sensitivity particularly in  gluten-containing grain and 
lactose play a major role in generating IBS symptoms. 
Food sensitivity is a treatable condition with clear 
pathogenesis, and we recommend that it be 
differentiated from IBS using the algorithm developed 
as a result of this audit project. Selection of the 
candidates for nutrition therapy based on the algorithm 
may help identifying individuals with a potential of 
optimal response to an elimination diet.   
It may be cheaper for health systems and deliver 
better outcomes for patients if elimination diets are 
used within current clinical guidelines.  The algorithm 
(Figure 5) would prioritise nutrition therapy above 
using medications with significant side effect profile 
(9), which are costly and may not be clinically effective 
in all cases. In addition, it would help to prevent further 
expensive investigations by providing an explanation 
for patients’ symptoms in a large proportion of patients 
(findings from this audit suggest it could be as high as 
72% of IBS patients). 
Dietary therapies are gaining popularity, as 
evidence of efficacy for specific diets has emerged. By 
undertaking dietary interventions, patients might not be 
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affected by  the side effects of medications currently 
used for their symptomatic relief. Dietary therapy also 
has the potential to confer financial benefits to health 
care providers who are already overstretched in caring 
for these patients. 
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